Ascentage Pharma Trustee Purchases 200,000 Shares for Restricted Share Unit Plan
Ascentage Pharma announced that a trustee purchased 200,000 existing shares in the open market to satisfy restricted share units under its 2022 plan.
Stocks · News reference
Ascentage Pharma announced that its trustee purchased 200,000 shares in the open market to fulfill obligations under its 2022 Restricted Share Unit (RSU) scheme.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Ascentage Pharma announced that a trustee purchased 200,000 existing shares in the open market to satisfy restricted share units under its 2022 plan.
Ascentage Pharma announced that lisaftoclax has been included in China's 2026 National Reimbursement Drug List (NRDL) for treating chronic lymphocytic leukemia/small lymphocytic lymphoma, while olverembatinib successfully renewed its NRDL coverage for chronic myeloid leukemia treatment. Both approvals take effect January 1, 2027, and represent all approved indications for both drugs now being covered by the NRDL, significantly improving patient access and affordability in China.
Ascentage Pharma announced that multiple clinical and preclinical studies for four of its proprietary drug candidates have been selected for presentation at the 68th American Society of Hematology (ASH) Annual Meeting.
Ascentage Pharma announced that its management team will participate in two upcoming investor conferences in London, United Kingdom.
William Blair sees major upside for Ascentage Pharma stock as the cancer drug developer approaches three pivotal trial results in 2027.